Dipsaci Radix EV Nanoparticles Activate BMP2/Smads for Osteogenesis

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

There is a lack of research on the extraction method and biological activity of extracellular vesicles (EVs) derived from dipsaci radix, a traditional Chinese medicinal material, limiting their application in treating orthopedic diseases such as osteoporosis and osteoarthritis.

Innovation Solution

DREVNs are extracted and purified from dipsaci radix, demonstrating the ability to be fully internalized by bone marrow mesenchymal stem cells (BMSCs), promoting osteogenic differentiation through the BMP2/Smads signaling pathway, and exhibiting bone targetability in vivo.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If EVs are extracted from dipsaci radix, then new therapeutic candidates for orthopedic diseases can be developed, but the feasibility and biological activity of DREVNs remain unknown due to limited studies

Engineering Contradiction:

Improveapplication potential in treating orthopedic diseasesVSAvoidbiological activity and feasibility

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent utilizes dipsaci radix, a traditional Chinese medicinal material that is low cost and readily available, to extract EVs for therapeutic application. This principle is applied by using inexpensive plant-based material as a source of bioactive nanoparticles, replacing expensive animal-derived or synthetic alternatives.

Inventive Principle:

Principle #27Cheap short-living objects (Disposable)

2Reliability

If DREVNs are used to promote osteogenic differentiation, then effective treatment for osteoporosis can be achieved, but the mechanism of action and targetability require verification

Engineering Contradiction:

Improveosteogenic differentiation effectVSAvoidmechanism verification complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent employs multiple detection methods including flow cytometry, confocal microscopy, and gene expression analysis to verify the internalization of DREVNs by BMSCs and their effect on osteogenic differentiation. This feedback mechanism confirms the biological activity and mechanism of action through quantitative and qualitative measurements.

Inventive Principle:

Principle #23Feedback

Solution Approach 2:

The patent replaces complex mechanical verification methods with molecular and cellular detection techniques. Instead of purely mechanical or physical verification, the study uses biochemical assays, gene expression analysis, and fluorescence imaging to confirm the mechanism of action and targetability of DREVNs.

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

3Ease of manufacture

If traditional Chinese medicinal materials are used as EV sources, then low cost and small side effects are achieved, but there are limited studies on EVs derived from these materials

Engineering Contradiction:

Improvelow cost and small side effectsVSAvoidlimited research data on plant EVs

Core Design Contradiction:

Ease of manufactureVSLoss of information

Solution Approach 1:

The patent uses dipsaci radix as an intermediary source to bridge traditional Chinese medicine and modern EV therapy. The EVs extracted from this plant material serve as a mediator that combines the advantages of traditional medicine (low cost, safety) with the innovative approach of EV-based therapy, filling the knowledge gap about plant-derived EVs.

Inventive Principle:

Principle #24Intermediary (Mediator)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

DREVNs effectively promote osteogenic differentiation and bone targetability, providing a new strategy for preventing or treating orthopedic diseases like osteoporosis and osteoarthritis.

Implementation Method 1

the EVs can be fully internalized by bone marrow mesenchymal stem cells (BMSCs)

Methodology Applied

Scientific EffectCellular internalization: Absorption (physical)

Implementation Method 2

can promote the osteogenic differentiation of BMSCs by activating a BMP2/Smads signaling pathway

Methodology Applied

Scientific EffectSignal transduction:

Data Source

PatentUS20250249062A1Use of dipsaci radix-derived extracellular vesicle-like nanoparticles in preparation of drug for preventing or treating orthopedic diseases

Publication Date: 2025.08.07 THE THIRD AFFILIATED HOSPITAL OF GUANGZHOU UNIV OF CHINESE MEDICINE

AI summary

Provided is a use of dipsaci radix-derived extracellular vesicle-like nanoparticles (DREVNs) in preparation of a drug for preventing or treating orthopedic diseases. In this application, EVs are creatively extracted from dipsaci radix and purified, and the physiological efficacy of the EVs is studied. It has been found that the EVs can be fully internalized by bone marrow mesenchymal stem cells (BMSCs), can promote the osteogenic differentiation of BMSCs by activating a BMP2/Smads signaling pathway, promote the calcified nodule formation in BMSCs, and promote the expression of osteogenic differentiation-associated genes ALP, OCN, RUNX2, and COL1, and have bone targetability in vivo. The EVs can be intragastrically administered to alleviate the osteoporosis (OP) in postmenopausal mice. Therefore, the EVs have the potential of being used to prepare drugs for preventing or treating orthopedic diseases, and provide a new strategy for the prevention or treatment of orthopedic diseases.